Berlin, Germany

Bernard Händler

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Certainly! Here is the article about inventor Bernard Händler.

Title: Pioneering Innovator: Bernard Händler

Introduction:

Bernard Händler, a distinguished inventor based in Berlin, Germany, is revered for his impressive contributions to the field of innovation. With a keen focus on transforming ideas into impactful technological solutions, Händler has made a significant mark in the realm of patents and inventions.

Latest Patents:

Händler's notable patent titled "Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease" showcases his pioneering work in developing effective treatments for hyper-proliferative diseases. The patent encompasses the use of Compound A, an inhibitor of ATR kinase, in treating subjects with such illnesses.

Career Highlights:

Throughout his career, Bernard Händler has been associated with renowned companies such as Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft. His expertise and innovative spirit have been instrumental in driving forward cutting-edge research and technological advancements in these esteemed organizations.

Collaborations:

During his tenure, Händler has collaborated closely with exceptional professionals in the field, including Antje Margret Wengner and Gerhard Siemeister. Together, they have worked on innovative projects that have paved the way for novel solutions in the realm of hyper-proliferative disease treatments.

Conclusion:

In conclusion, Bernard Händler stands as a true pioneer in the world of innovation, with a remarkable track record of transforming ideas into tangible solutions that shape the future of technology. His groundbreaking work in developing treatments for hyper-proliferative diseases underscores his unwavering commitment to driving positive change through inventive solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…